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SUMMARY
Echinococcus granulosus and Echinococcus multilocularis are cestode parasites, of which the metacestode (larval) stages cause
the diseases cystic echinococcosis (CE) and alveolar echinococcosis (AE), respectively. Albendazole and mebendazole are
presently used for chemotherapeutical treatment. However, these benzimidazoles do not appear to be parasiticidal in vivo
against AE. In addition, failures in drug treatments as well as the occurrence of side-eﬀects have been reported. New drugs
are needed to cure AE and CE, which are considered to be neglected diseases. Strategies currently being implemented to
identify novel chemotherapeutical treatment options include (i) conventional primary in vitro testing of broad-spectrum
anti-infective drugs, either in parallel with, or followed by, animal experimentation; (ii) studies of drugs which interfere
with the proliferation of cancer cells and of Echinococcus metacestodes; (iii) exploitation of the similarities between the
parasite and mammalian signalling machineries, with a special focus on targeting speciﬁc signalling receptors; (iv) in silico
approaches, employing the current Echinococcus genomic database information to search for suitable targets for com-
pounds with known modes of action. In the present article, we review the eﬀorts toward obtaining better anti-parasitic
compounds which have been undertaken to improve chemotherapeutical treatment of echinococcosis, and summarize the
achievements in the ﬁeld of host-parasite interactions which may also lead to new immuno-therapeutical options.
Key words: cystic echinococcosis (CE), alveolar echinococcosis (AE), chemotherapy, immunotherapy, signalling, drugs,
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ECHINOCOCCUS AND ECHINOCOCCOSIS
Echinococcosis, caused by the larval stages of the
cestode parasite of the genus Echinococcus, is a life-
threatening disease of serious public health and
economic concern of global proportion (Torgerson,
2003; Eckert and Deplazes, 2004). Four distinct
species within the genus Echinococcus have been
identiﬁed i.e. Echinococcus multilocularis, E. granu-
losus, E. vogeli and E. oligarthrus (Thompson, 1986).
All Echinococcus species are potentially zoonotic, but
only 2 are of signiﬁcant medical importance in hu-
mans: E. multlilocularis (small fox tapeworm) being
the most pathogenic parasite, and E. granulosus (dog
tapeworm) being the commonest (Rausch, 1995;
McManus et al. 2003).
E. multilocularis infection causes alveolar echino-
coccosis (AE) in intermediate hosts (rodents) and
humans, and is restricted to the northern hemi-
sphere. In contrast,E. granulosus, the causative agent
of cystic echinococcosis (CE) that occurs worldwide
(Schantz et al. 1995). The habitat of the adult worms
is the small intestine of their respective deﬁnitive
host (canids for E. granulosus, and canids and felids
for E. multilocularis), where sexual reproduction and
subsequent egg production take place. Eggs released
in the faeces into the environment, where they are
accidentally ingested by suitable intermediate hosts,
such as small rodents for E. multilocularis, and
mainly livestock for E. granulosus. Humans rep-
resent an aberrant intermediate host, acquiring the
disease through the accidental ingestion of eggs,
with serious consequences. Each egg contains an
oncosphere (=ﬁrst larval stage), which actively
penetrates the intestinal lining and is transported
via the blood and lymph to the sites of predilection/
establishment. Aﬀected organs in humans are
mainly the liver for E. multilocularis and the liver and
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lung in the case of E. granulosus. In these sites, the
oncospheres develop into metacestodes (=second
larval stage). Within these metacestodes, via asexual
reproduction, brood capsules and protoscoleces form
in natural intermediate hosts. If the metacestode in/
from an infected intermediate host is ingested by a
suitable deﬁnitive host, the life-cycle is concluded.
Protoscolex development in humans has only rarely
been described (Gottstein and Hemphill, 1997).
Metacestodes represent the disease-causing stage.
They are ﬂuid-ﬁlled cysts with cellular and acellular
compartments (Fig. 1). The outer, acellular surface
of the metacestode is formed by the laminated layer,
a carbohydrate-rich structure, synthesized by the
parasite, which, in terms of thickness, is much more
prominent in E. granulosus than E. multilocularis
metacestodes (Gottstein and Hemphill, 1997). In
addition, E. granulosus metacestodes are surrounded
by a very prominent host-derived ﬁbrous capsule,
the adventitial layer, which is composed of host
connective tissue. The laminated layer plays a cru-
cial role in the survival strategy of the parasite
by modulating immunological and physiological
reactions of the host (Gottstein et al. 2002; reviewed
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Fig. 1. Morphology and ultrastructure of Echinococcus metacestodes. (A) E. multilocularis metacestode, cut open to view
the germinal layer with developing brood capsules (arrow); (B) SEM of brood capsules (bc) containing developing
protoscoleces ; (C) E. granulosus metacestode cultured in vitro ; (D) SEM showing laminated layer and germinal layer
of E. multilocularis metacestode; (E) SEM of laminated layer and germinal layer of E. granulosus metacestode; (F) SEM
of germinal layer-associated tissue of E. multilocularis ; (G) TEM of E. granulosus metacestodes showing laminated
layer, tegument and germinal layer. GL=germinal layer, LL=laminated layer, Te=tegument, arrows in (G) point
towards microtriches.
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in Siles-Lucas and Hemphill, 2002). The actual
larval tissue is formed by the germinal layer, the
distal part of which consists of the tegument which
is directly associated with the inner surface of the
laminated layer. The tegument is characterized by
microvilli-like extensions termed microtriches,
which protrude well into the matrix of the laminated
layer and increase the resorbing surface of the para-
site. In addition, the germinal layer contains highly
diﬀerentiated cell types, including connective tissue,
muscle cells, glycogen storage cells and many un-
diﬀerentiated cells (Eckert et al. 1983).
Typically, the fully mature E. granulosus meta-
cestode (i.e. hydatid cyst) is a single-chambered or
septated but usually unilocular cyst, which displays
expansive growth, causing a compression of neigh-
bouring tissue and resulting in organ dysfunction
and disease (Kern, 2003, 2006). In E. multilocularis
infection, the metacestode represents a multi-
vesicular structure which reproduces (also asexually)
by exogenous formation and budding of daughter
vesicles, which resembles progressive tumour-like
growth (Ohbayashi et al. 1971; Ali-Kahn et al.
1983). This growth leads to the a large and hetero-
genous mass of the parasite characterized by mostly
peripheral actively proliferating areas and, in many
cases, centrally located necrotic tissue. Metastases
can occur in other organs following the release of
germinal layer cells into the blood or lymph system




Traditionally, the treatment of echinococcosis relies
primarily on surgery and/or chemotherapy, and
the treatment strategy depends largely on diﬀerent
factors, such as metacestode size and location,
viability status, the interaction between the expand-
ing parasite and the adjacent host tissue, complicat-
ing bacterial or fungal infection and potential
complications related to cyst rupture and spillage of
protoscoleces (Kern, 2003, 2006).
In CE, radical resection of the cyst mass re-
presents the traditional treatment strategy and is, in
many instances, accompanied by chemotherapy
prior to and following surgery. Protoscolicidal sub-
stances are often applied, since there is a risk of
spillage of cyst ﬂuid containing protoscoleces,
which can lead to metastases (Stey and Jost, 1993;
Pawloski, 1997; Kern, 2003, 2006). PAIR (punc-
ture, aspiration, injection, re-aspiration) is a tech-
nique that was introduced in the mid-eighties, and
includes percutaneous puncture of the cysts under
ultrasonic guidance, aspiration of substantial
amounts of cyst ﬂuid, injection of protoscolicidal
substance (e.g. 95% ethanol), and re-aspiration of
the ﬂuid cyst content after 15–20 min. Although
the eﬃcacy and potential risks have not been fully
evaluated, and more long-term studies are needed,
PAIR has been used in several hundred patients
(Eckert and Deplazes, 2004; Brunetti et al. 2004).
For inoperable cases, chemotherapy applying ben-
zimidazoles is the only option. There are over 2000
well-documented inoperable cases of CE, which
have undergone treatment with benzimidazoles.
When evaluated up to 12 months after initiation of
chemotherapy, cysts disappeared in 30% of patients,
cysts degenerated in 50–70%, indicating improve-
ment, and in 20–30% of patients E. granulosus
metacestodes did not respond to chemotherapy
(Pawloski et al. 2001). Praziquantel (PZQ), a het-
erocyclic pyrazinoisoquinoline derivative has been
proposed for use together with benzimidazoles in
CE patients. PZQ exhibits a high eﬃcacy against
protoscoleces and metacestodes in animal experi-
ments (Urrea-Paris et al. 1999, 2001), and the
combined treatment with ABZ and PZQ given
during the month prior to surgery has been shown
to increase the number of human patients with non-
viable protoscoleces as compared to therapy with
ABZ alone (Cobo et al. 1998).
For the treatment of AE, surgery, if applicable,
is accompanied by chemotherapy using benzimida-
zoles, which should be maintained for at least 2 years
following surgery, and the monitoring of patients
should be continued for 10 years (Pawloski et al.
2001). Inoperable AE cases must undergo long-
term, often life-long, chemotherapy with albenda-
zole (ABZ) and/or mebendazole (MBZ) (Reuter
et al. 2000, 2004). Extensive animal experimentation
and observations in human patients suﬀerering
from AE have demonstrated that ABZ and MBZ
exhibit a parasitostatic rather than a parasitocidal
eﬀect (El-On, 2002; Reuter et al. 2004). Thus, ben-
zimidazoles only prevent E. multilocularis growth,
and the recurrence rates after interruption of therapy
are high. Nevertheless, clinical studies have shown
that chemotherapy has signiﬁcantly increased the
10-year survival rate of inoperable or non-radically
operated AE patients from 6–25% to 80–83%
(Ammann and Eckert, 1995. Eckert and Deplazes,
2004). Spontaneous cure of AE, leading to calciﬁed
lesions is possible, but it is not known how fre-
quently calciﬁcation occurs (reviewed by Gottstein
and Hemphill, 1997; Vuitton et al. 2006). Large
surveys in endemic areas have shown that the num-
ber of patients with established AE is considerably
lower than the number of seropositive humans ex-
posed to the eggs of E. multilocularis (see Rausch
et al. 1987; Bresson-Hadni et al. 1994; Bartholomot
et al. 2002). This information suggests that immun-
ity in humans is capable of killing the parasite after
infection, which could facilitate the development of
immunotherapeutical tools.
The clinical application of benzimidazoles for the
treatment of AE and CE was accompanied by studies
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employing animal models, focusing on comparing
the activities of diﬀerent benzimidazole derivatives,
and on diﬀerent formulations and modes of ap-
plication. The eﬃcacies of oral administration were
demonstrated to be dependent on the duration
of treatment and the age of the parasite. Eﬃcacy
increases with the duration of treatment, but is de-
creased for infections which have persisted for long
periods of time (over 6 months in mice) (Wangoo
et al. 1987). Increasing doses produced better re-
sults, although clear parasitocidal eﬀects were not
achieved (Taylor et al. 1989), and observations con-
sistent with drug resistance were described (Morris
and Taylor, 1990). There are conﬂicting reports of
the most suitable mode of administration of benzi-
midazoles. It was postulated that parenteral admin-
istration of benzimidazoles resulted in a higher
eﬃcacy than other routes in animals experimentally
infected with E. multilocularis (reviewed by Siles-
Lucas and Hemphill, 2002). Drug combinations,
normally consisting of one benzimidazole and one or
more other compound, were tested in order to obtain
better treatment eﬃcacies. For instance, synergistic
eﬀects were reported for combinations of ABZ with
the dipeptide methyl ester Phe-Phe-OMe (Sarciron
et al. 1997). In addition, novel formulations of ben-
zimidazoles, either as pro-drugs (Walchshofer et al.
1990), liposome-entrapped compounds (Wen et al.
1996) or colloidal, intravenously injectable formu-
lations (Rodrigues et al. 1995) were tested in rodents
and showed enhanced eﬃcacy at lower doses than
the parental compounds. However, these studies
have not yet been translated into clinical appli-
cations, with one exception: Chai et al. (2004) re-
ported on improved eﬃcacy of ABZ emulsion
compared with ABZ tablets or capsules for the
treatment of liver CE.
Adverse reactions against benzimidazoles under
long-term chemotherapy include elevation of trans-
aminases, proteinuria, hair loss, gastrointestinal
disturbances, neurological symptoms (vertigo/diz-
ziness), leukopaenia, headache, abnormal liver
biopsy, abdominal pain, fever, urticaria, thrombo-
cytopaenia, allergic shock (due to cyst collapse and
release of E. granulosus cyst ﬂuid) and toxicity to
bone marrow. A study comprised of 3282 echino-
coccosis patients treated with ABZ showed that
most side-eﬀects were associated with the gastro-
intestinal tract (Pawloski, 1997; Kern, 2003), but
no fatal cases involving ABZ therapy have been
described. In 3.8% of these cases, permanent dis-
continuation of treatment had to be undertaken.
As suggested by animal experimentation (Horton,
1989, 1997), MBZ and ABZ may induce embryo-
toxic or teratogenic eﬀects, and it is recommended
that these drugs are not used for the treatment
of pregnant women. Constant monitoring of drug
levels in serum is suggested in order to prevent toxic
reactions.
TOWARDS THE DEVELOPMENT OF IMMUNO-
THERAPEUTICAL APPROACHES FOR THE
TREATMENT OF ECHINOCOCCOSIS
Considerable eﬀort has gone into elucidating the im-
munological basis of the host-parasite relationship
during infection with Echinococcus. In both AE
and CE, the initial immune responses during the
primary phases of infection are characterized by a
predominantly Th1-type response, whereas in the
later stages of disease progression, the immune re-
sponse switches to a Th2 polarized proﬁle (Gottstein
et al. 2006; Vuitton et al. 2006; Zhang and
McManus, 2006). In addition, one of the hallmarks
of most helminth infections is the occurrence of a
profound immuno-modulation and -suppression
(Maizels and Yazdanbakhsh, 2003). Hence,
E. granulosus and E. multilocularis have a signiﬁcant
inﬂuence on the immune response in their hosts. For
both E. multilocularis and E. granulosus, it has been
shown that carbohydrate moieties or carbohydrate-
rich fractions possess immunomodulatory properties
(Dai et al. 2001; Dematteis et al. 2001; Walker et al.
2004a ; reviewed by Baz et al. 2006). This infor-
mation is in accordance with ﬁndings of studies
investigating the involvement of glycans in im-
munomodulation during helminth infections
(Maizels and Yazdanbakhsh, 2003), and the current
challenge is to translate this knowledge into novel
immuno-therapeutical applications.
Cystic echinococcosis
Some insights into the initial phases of CE have been
obtained using experimental E. granulosus infection
in sheep or mice (Baz et al. 2006; Zhang and
McManus, 2006). The initial low-level Th1-biased
immune response following the infection is ac-
companied by an inﬁltration of macrophages and
eosinophils and the development of a weak humoral
immune response. Conversely, established cysts in
experimentally infected animals and in human
patients are capable of modulating the immune
response, resulting in a Th2-polarized proﬁle ex-
hibiting the production of IL-4, IL-5, IL-6 and
IL-10 and balanced by Th1 cytokines, such as
IFN-c. Upon the death of an E. granulosus cyst
either naturally or due to chemotherapy, levels of
Th2 cytokines decrease rapidly and the immune
response polarizes towards Th1; upon relapse, Th2
responses regenerate within a few weeks. This Th1-
Th2 co-existence and inter-conversion during CE is
likely to be mediated by E. granulosus antigens.
Examples of antigens which bear epitopes which can
induce both Th1 and Th2 responses are Eg2HSP70,
EgA31 and Eg/Trp, (Ortona et al. 2003; Fraize et al.
2005). Another eﬃcient strategy which contributes
to the parasite survival strategy is the disruption of
eﬀector mechanisms of the host immune repsonse.
In a study of E. granulosus, Diaz and co-workers
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showed that the activation of complement is
inhibited by the binding of the host inhibitory
Factor H to the hydatid cyst wall. The same authors
investigated the consumption of complement com-
ponents by molecular factors within the hydatid
cysts (Diaz et al. 1999; Ferreira et al. 2000, 2001).
In addition, T cell responses were shown to be
modulated by the intensity of infection, as de-
monstrated in mice infected with diﬀerent doses of
E. granulosus protoscoleces (Dematteis et al. 2003).
The generation of T cell lines from patients ex-
hibiting diﬀerent courses of disease (harbouring
active, transitional or inactive cysts) and subsequent
stimulation of these cells with hydatid ﬂuid and/?or?
a deﬁned E. granulosus antigen (AgB) has also shown
that Th1 cells contribute to the inactive stage of
hydatid disease, whereas Th2 cells have been shown
to be more important in the active and transitional
stages (Rigano et al. 2004). Interestingly, patients
undergoing chemotherapy with benzimidazoles ex-
hibited a more pronounced Th1 cytokine proﬁle,
reﬂecting the regression of the metacestode (Rigano
et al. 1995). Self cure of CE, leading to calciﬁed
cysts, is common in sheep and also in the human
population in hyperendemic regions (MacPherson
et al. 2004;Moro et al. 2005), and cytokines are likely
to play a key role in these processes. Elucidating the
factors involved in cyst calciﬁcation could lead to
novel therapeutical approaches.
Alveolar echinococcosis (AE)
In accordance with E. granulosus infection in hu-
mans, Th1 responses dominate the early stages of
E. multilocularis infection, with the immune re-
sponse switching to Th2 at the chronic stage of dis-
ease (Zhang and McManus, 2006). Antibody levels
are low initially, but levels of IgG1 and IgG3
increase during infection. In human patients, a
strong cellular immune response is a characteristic
hallmark, resulting in granulomatous inﬁltrate sur-
rounding the parasite lesions (Vuitton et al. 1989;
Grenard et al. 2001). In patients with abortive or
dead lesions, the cells contributing to this granuloma
formation are mostly macrophages, myoﬁbroblasts
and a large number of CD4+T cells, and in patients
exhibiting a progressive clinical course of AE, there
is an increased number of CD8+T cells (Manfras
et al. 2002). This corresponds to ﬁndings in mice,
which have shown that E. multilocularis metaces-
todes exhibit a considerably increased growth in
nude, TCR-b (x/x) and MHC-II (x/x) mice
compared with wild type C57BL/6 mice, with the
T cell-deﬁcient mice dying 2 months after infection
(Dai et al. 2004). Thus, CD4+ab+ T cells play a
growth-limiting role in E. multilocularis infection.
A further hallmark of AE is the development of
ﬁbrosis surrounding the parasite. In human patients,
ﬁbrotic processes are frequently observed, even
distant from the lesions caused by the parasite,
suggesting a major role for cytokines in collagen
synthesis and cross-linking (Vuitton et al. 2006).
There are indications that ﬁbrotic processes
might be directed by the parasite itself. A parasite
trans-glutaminase has been shown to be strongly
expressed in and at the border of metacestodes, and
this enzyme was capable of cross-linking human
collagen in vitro (Grenard et al. 2001). Fibrosis itself,
in addition to the outer acellular laminated layer,
could be responsible for keeping cytolytic immune
cells away from the parasite tissue.
The observation that a strong cellular immunity
renders mice less susceptible to disease and that Th1
type immune responses, as assessed by correspond-
ing cytokines, may kill the parasite or prevent its
development suggests that immuno-therapeutical
tools could be developed to combat echinococcosis.
This notion is supported by evidence that the
stimulation of the immune system with Bacille
Calmette Guerin (BCG) has been reported to exhibit
a profound reductive eﬀect on the size and dissemi-
nation of E. multilocularis metacestodes in rodents
(Rau and Tanner, 1975). However, despite encour-
aging clinical results, there are no reports on the
limited BCG-trials in human patients (Vuitton et al.
2006).
Another immuno-stimulating compound, Iso-
prinosineTM, has been shown to have a good eﬃcacy
against E. granulosus and E. multilocularis meta-
cestodes and protoscoleces in vitro as well as in mice
and jirds (Sarciron et al. 1992, 1993, 1995; Lawton
et al. 2001). The drug has been applied in patients
with AE, and has shown a regression of parasite
lesions in 2 patients (reviewed by Vuitton et al.
2006). This compound acts through stimulating
cellular immunity, increasing IL-1, IL-2 and IFN-
c-production, and inhibiting Th2 type immune re-
sponses, including IgE-dependent reactions.
The pre-treatment of mice with IL-12 has been
shown to eﬃciently limit the development of para-
site lesions, resulting in aborted metacestode vesicles
surrounded by inﬁltrative cells and ﬁbrosis (Emery
et al. 1998). However, IL-12 treatment has not been
evaluated as a therapeutic agent in human AE
patients because of potential side-eﬀects.
Liance et al. (1998) reported that the in vivo
treatment of mice with a low dose (1 mg, twice a
week for 3 weeks) of IFN-c decreased metacestode
growth and liver ﬁbrogenesis. The eﬀect was dose-
dependent, as the treatment with a higher dose (5 mg,
twice a week for 3 weeks) increased the number of
metacestodes in the liver. Two case reports docu-
mented the clinical eﬃcacy of IFN-c-treatment.
One patient suﬀering from severe side-eﬀects caused
by ABZ-therapy was treated with IFN-c during a
3-day period once a month, and this treatment pre-
vented disease progression but did not alter the Th2-
dominated immune response against this parasite
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(Jenne et al. 1998). Another patient whose lesions
were growing, despite mebendazole therapy, was
treated with a combination of IFN-c and mebenda-
zole, which halted the progression of disease as
revealed in a 1-year follow-up period (Schmid et al.
1995).
The treatment of mice with IFN-a-2a has been
shown to largely prevent the formation of hepatic
lesions in infected mice, with an inhibition of IL-10,
IL-6 and IL-13 antigen-induced secretion in spleen
cell cultures (Godot et al. 2003). One patient with
AE and chronic hepatitis C was treated eﬀectively
with IFN-a-2a, suggesting that this cytokine limited
parasite growth and reversed the cytokine proﬁle to
Th1 (Harraga et al. 1999). Thus, IFNa-2a seems to
be the most promising candidate for, for instance,
further clinical investigation, because it is already
widely used for treating chronic viral infections.
However, more studies are required to assess the
ambiguous role of this cytokine.
SEARCHING FOR NOVEL CHEMOTHERAPEUTICAL
OPTIONS
As discussed, novel and improved therapeutical
tools are needed in order to optimize treatment of
CE and AE. Both in vitro and in vivo laboratory
models have been used for drug evaluation (re-
viewed by Siles-Lucas and Hemphill, 2002).
Unfortunately, besides the initial development of
benzimidazoles, the pharmaceutical industry has not
expressed a keen interest in supporting the discovery
of novel treatment options. Therefore, AE and CE
must be regarded as neglected diseases.
Historically, the primary assessment of anti-
echinococcal drug candidates has often been per-
formed in rodents (mice or gerbils), which has led
to the extensive use of animal experimentation.
Subsequently, the in vitro culture of Echinococcus
metacestodes has proven to be a suitable tool for
the primary assessment of parasite susceptibility to
certain compounds, with a focus on broad-spectrum
anti-infective agents, and also represents an ideal
model system for studies on drug uptake and asso-
ciated metabolic changes imposed upon the parasite
(Hemphill et al. 2002). More recently, optimized in
vitro culture conditions (Spiliotis et al. 2004) have
allowed the dissection of the molecular nature of
the signalling machinery within E. multilocularis
metacestodes required for communication at the
host-parasite interface (reviewed by Brehm et al.
2006). These studies have provided extensive infor-
mation on novel potential drug targets associated
with the parasite signalling network. Although the
availability of genomics and related technologies
provides avenues for the application of modern
approaches, the current genomic and expressed
sequence tag (EST) information on Echinococcus is
still limited. Nonetheless, the generation of more
EST data is underway (see http://www.sanger.
ac.uk/Projects/Echinococcus/) and will be an ex-
tremely valuable resource for gene expression
studies.
The following strategies are currently being
followed in order to identify novel alternative
chemotherapeutical treatment options: (i) conven-
tional primary in vitro testing of broad-spectrum
anti-infective drugs, either in parallel with, or
followed by, animal experimentation; (ii) studies on
drugs which interfere with the uncontrolled pro-
liferation of cancer cells and aﬀect the viability of
Echinococcus metacestodes and protoscoleces;
(iii) exploitation of the similarities between the
parasite and mammalian signalling machineries,
with a special focus on targeting speciﬁc signalling
receptors ; (iv) in silico approaches, employing the
current Echinococcus genomic database information
to search for suitable targets for compounds of
known mode of action.
(i) Chemotherapeutical activities of anti-infective
drugs
In vitro chemotherapy studies of CE have mostly,
but not exclusively, focused on protoscoleces, since
these are easily cultured, and their diﬀerentiation
into metacestodes is a time-consuming process that
can easily take 4–6 months (Walker et al. 2004b).
Experimental prophylactic therapy of E. granulosus
protoscoleces was carried out as a model that would
mimic spillage during surgery, by treating pro-
toscoleces with PZQ (Urrea-Paris et al. 2001) or a
combination of PZQ and ABZ (Casado et al. 2001)
prior to injection into mice. Respective ﬁndings are
of substantial clinical relevance. Other promising
compounds with in vitro protoscolicidal actions were
cetrimide (Frayha et al. 1981) and the ionophore
monensin (Rogan and Richards, 1986), but these
drugs were found to be rather ineﬀective against
metacestodes. Levamisole and ivermectin, which are
classically nematocidal, were shown to exhibit in
vitro activities similar to benzimidazoles (Martinez
et al. 1999). Against E. granulosus infection in ro-
dents, a combination of fenbendazol and netobimin
(Garcia-Llamarez et al. 1997) showed synergistic
eﬀects, allowing the administration of lower drug
dosages. Oxfendazole, like ABZ, is a benzimidazole,
used in veterinary medicine for the treatment of
nematode infections, and has a similar antimicrobial
spectrum but a longer half-life. Experimental treat-
ments of naturally E. granulosus-infected sheep and
goats suggested that oxfendazole may be as eﬃ-
cacious as ABZ, but does not require daily uptake of
the drug because of its prolonged bioavailability
(Blanton et al. 1998; Dueger et al. 1999). Xiao et al.
(1995) studied the eﬀects of several drugs on en-
zymes involved in carbohydrate metabolism and
found that some of the corresponding host enzymes
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were not aﬀected, thus identifying novel potential
drug targets. Cyclosporin A, employed mainly as an
immunosuppressant during the management of
organ transplants, also exhibits anti-echinococcal
activity. While the administration of cyclosporin
A in 5 consecutive daily doses, beginning 2 days
prior to the infection of mice with E. granulosus
protsocoleces, resulted in a signiﬁcant reduction in
cyst numbers and cyst masses measured at 20 weeks
after infection; no changes in cyst mass and numbers
were recorded when the drug was administered
18 weeks after infection, but the wet weight was
decreased by 42% compared with untreated con-
trols. Ultrastructural examination of the germinal
membrane and laminated layer of late-treated
E. granulosus revealed abnormalities in all cysts
studied, whereas control and early-treated hydatids
were normal (Hurd et al. 1993).
In rodents infected with E. multilocularis meta-
cestodes, mytomicin C, piperazine and quinolone
derivates, alkylaminoethers and propargylic alcohols
exhibited parasitostatic eﬀects, at either a lower or
comparable level as benzimidazoles (reviewed by
Siles-Lucas and Hemphill, 2002). PZQ has been
used for the treatment of AE, but experimental data
in animals have shown that the eﬃcacy of PZQ
against E. multilocularis metacestodes was inad-
equate (Marchiondo et al. 1994). Also, the treatment
of E. multilocularis-infected mice with alpha-
diﬂuoromethylornithine was not successful (Miyaji
et al. 1993). In contrast to its use against CE,
cyclosporin A did not have any anti-parasitic activity
against E. multilocularis infection in experimentally
infected mice, and its immunosuppressive activity
was shown to be more eﬀective than its parasitostatic
eﬀect (Liance et al. 1992).
Nitazoxanide (NTZ), a broad-spectrum anthel-
minthic also used for treatment against enteric
bacteria, Giardia and Cryptosporidium (cf. Hemphill
et al. 2006), was identiﬁed as a compound inducing
signiﬁcant distortion of the germinal layer in vitro,
and NTZ-treated E. multilocularis metacestodes
were non-viable when introduced into susceptible
mice (Stettler et al. 2003). NTZ was also found
to induce severe damage to E. granulosus proto-
scoleces and the germinal layer of in vitro-cultured
E. granulosus metacestodes (Walker et al. 2004b).
NTZ represents the parent compound of a class of
drugs named thiazolides, which include modiﬁed
variants of NTZ (Hemphill et al. 2006; Esposito
et al. 2007). In vitro studies of E. multilocularis and
E. granulosus employing NTZ-derivatives have
shown that metacestodical and protoscolicidal ac-
tivities of this class of drugs strongly depend on
the presence of the nitro-thiazole moiety, suggesting
that this nitro-group is instrumental for the
activity of thiazoldies (Naguleswaran and Hemphill,
unpublished ﬁndings). These promising results
indicate the potential of NTZ and possibly other
thiazolides as novel anti-echincoccocal compounds
(Craig, 2003).
Recently, Reuter et al. (2006) investigated
the eﬃcacy of a series of compounds against
E. multilocularis metacestodes, including ABZ,
artemether, caspofungin, itraconazole (ITZ), iver-
mectin, methiazole (MTZ), miltefosine, NTZ,
rifampicin and trimethoprim/sulfamethoxazole.
They found that ABZ, ITZ, MTZ and NTZ eﬀ-
ectively destroyed parasite vesicles in vitro.
However, after drug discontinuation, re-growth of
vesicles occurred, indicating a parasitostatic eﬀect
only. Combination treatment with ABZ/NTZ at
concentrations between 1 and 10 mg/ml for 3 weeks
yielded no re-growth of parasites during 8 months
of drug discontinuation, and the subsequent evalu-
ation in a bioassay in gerbils did also not
result in viable parasite infections. These results
indicated that combined ABZ/NTZ treatment
exhibits a parasitocidal eﬀect. In this respect,
Stettler et al. (2004) have shown that NTZ, applied
orally to E. multilocularis-infected mice, either alone
or in combination with ABZ, exhibited a profound
anti-parasitic eﬃcacy, with the ABZ/NTZ combi-
nation yielding the most promising outcome.
Electron microscopical analysis of metacestode
tissue obtained from treated mice suggested that the
ABZ/NTZ combination exerted a synergistic eﬀect.
However, the pharmacokinetic analysis of cor-
responding serum levels in mice showed that the
application of ABZ in combination with NTZ
increased considerably the ABZSO-levels and also
the half-life of ABZSO (Stettler et al. 2004).
Therefore, the increased eﬃcacy observed in
mice could be the result of both direct eﬀects of
NTZ and ABZ metabolites and increased avail-
ability of ABZSO in mice receiving the combination
treatment.
Amphotericin B desoxycholate (cAMB), an anti-
fungal compound, was shown to eﬀectively inhibit
the growth of E. multilocularis metacestodes in vitro
and in human patients in vivo (Reuter et al.
2003a, b). A major limitation of cAMB is its mode
of administration (intravenous), which makes it
unsuitable for prolonged use, except for salvage
treatment (Reuter et al. 2003b). Also, the eﬀect
of cAMB is only parasitostatic and the drug is ne-
phrotoxic, limiting its widespread use. Nevertheless,
prolonged application of cAMB for months to years
may be feasible in some cases, as side-eﬀects are mild
and serious organ damage does not appear to occur
(Reuter et al. 2003b).
(ii) Anti-cancer drugs and echinococcosis
There are a number of similarities between cancer
cells and some parasites, particularly Echinococcus
(reviewed by Klinkert and Heussler, 2006).
Similarities include features, such as the essentially
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unlimited proliferative capacity of protoscoleces/
brood capsules, the potential to modulate the im-
mune response, the secretion of proteolytic enzymes
to reach their target sites or organs, and the
formation of metastases. E. multilocularis metaces-
todes behave like malignant tumours, and there is an
association between the uncontrolled proliferation
and growth and the over-expression in metacestodes
of a family of proteins named 14-3-3 (Siles-Lucas
et al. 1998, 2001). 14-3-3 proteins are found in all
eukaryotic cells and participate in protein kinase
signalling pathways. They function as phosphoser-
ine/phosphothreonine-binding modules and have an
eﬀect on phosphorylation-dependent events, such as
DNA-damage checkpoints and prevention of apop-
tosis (reviewed by Siles-Lucas and Gottstein,
2003). Some 14-3-3 proteins have been found to be
aberrantly expressed in tumour cells, acting either
pro-or anti-tumourogenically. Indeed, when Echino-
coccus 14-3-3 sequences are aligned with other
14-3-3 isoforms of other organisms, those over-
expressed in metacestodes can be grouped with the
tumour-growth related zeta-isoforms (Siles-Lucas
et al. 2001). This information suggests that certain
anti-tumour agents could interfere with the growth
of Echinococcus metacestodes.
Doxorubicin, or hydroxyldaunorubicin, is a
DNA-interacting drug used widely in the treatment
of a wide range of cancers (Launchbury and
Habboubi, 1993). The parasiticidal properties of
doxorubicin bound to polyisohexylcyanoacrylate
nanoparticles (a colloidal biodegradable drug car-
rier) were assessed against the metacestode of
E. multilocularis (see Liance et al. 1993). A reduction
of the development of the parasite in the liver and a
reduced viability of the metacestode were observed
in mice injected with 5 mg/kg body weight, but
7.5 mg/kg body weight did not appear more eﬃcient.
Free doxorubicin or unbound nanoparticles had no
anti-parasitic activity (Liance et al. 1993).
Another class of anti-cancer agents with
proven anti-parasitic activities are isoﬂavonoids.
Isoﬂavonoids are substances formed by plant tissue
in response to physiological stimuli, such as infec-
tious agents, with reported anti-oxidant, -bacterial,
-viral and -fungal activities (Dakora and Philipps,
1996). They are composed of a characteristic
15-carbon backbone ring structure connected by a
heterocyclic pyrane (3-C) bridge (C6-C3-C6)
(Reynaud et al. 2005), with the 2 aromatic rings
generally containing a number of phenolic hydroxyl
groups. Genistein, a major component of soya, is the
most prominent isoﬂavonoid, and inhibits growth
and metastasis of a number of cancer cell lines
(breast, prostate, skin and colon) (Messina, 1999).
Genistein also stimulates the synthesis of TGF-b,
which itself inhibits cancer cell proliferation
(Messina, 1999). Besides other targets, genistein acts
on a number of signalling pathways by functioning
as a kinase inhibitor (tyrosine kinase, MAP kinase,
ribosomal S6 kinase). Recent studies have shown
that genistein is highly eﬀective against E. multi-
locularis metacestodes in vitro (Naguleswaran et al.
2006). However, genistein has a disadvantage, in
that it also exerts oestrogenic eﬀects by binding to
oestrogen receptor-b, which renders genistein un-
favourable for long-term treatment. Binding to the
oestrogen receptor-b has been proven to take
place through the hydroxyl-group associated with
the B-ring of the molecule. Therefore, a number
of isoﬂavonoids that do not carry this hydroxyl-
group have been tested in vitro and do not meet
the steric requirements to bind to the oestrogen re-
ceptor-beta. One of these compounds, Rm6423,
exhibits a pronounced anti-parasitic activity against
E. multilocularis metacestodes as well as against
E. granulosus metacestodes and protoscoleces
(Naguleswaran et al. 2006). Moreover, an examin-
ation of culture medium revealed increased leakage
of parasite proteins into the medium during treat-
ment, and zymography demonstrated a loss of the
activity of metalloproteases. The molecular basis of
the eﬃcacy of genistein and its derivative Rm6423
has not yet been elucidated, but these compounds
could interfere in signalling, for instance, through an
inhibition of the tyrosine kinase activity associated
with the epidermal growth factor receptor identiﬁed
in E. multilocularis (see Spiliotis et al. 2006).
An endogenous metabolite of oestrogen with both
anti-angiogenic and anti-tumour eﬀects, 2-methox-
yestradiol (2-ME) (reviewed by Schumacher and
Neuhaus, 2001) has been shown to down-regulate
the pro-tumourogenic 14-3-3-f-isoform in a num-
ber of cancer cell types (Kumar et al. 2003). The
pro-tumourogenic 14-3-3-f-isoform is also over-
expressed in Echincoccus metacestodes (Siles-Lucas
and Gottstein, 2003), and the exposure of 2-ME
(2–10 mM) to E. multilocularis metacestodes in vitro
severely damaged them in a dose-dependent man-
ner. In parallel, drug treatment also down-scaled
14-3-3 transcription compared with actin expression
(Naguleswaran et al. unpublished ﬁndings). Al-
though it is not known how 2-ME exerts its eﬀects
on Echinococcus, the mechanism of action of 2-ME
in cancer cells has been attributed to an interference
with microtubule stability and a disregulation of
the hypoxia-inducible factor (Klauber et al. 1997;
Mabjeesh et al. 2003) inducing cancers cells to
undergo apoptosis via extrinsic and intrinsic path-
ways.
(iii) The Echinococcus signalling machinery as a
novel drug target
More recently, the excellent work of Brehm et al.
(2006) has shed light on the factors involved in host-
parasite communication in AE. E. multilocularis
metacestodes express a number of developmental
A. Hemphill and others 1664
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S0031182007003198
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 30 May 2017 at 15:12:58, subject to the Cambridge Core terms of use, available at
factors which they share with other metazoans.
These include signalling systems which employ
receptor tyrosine kinases of the epidermal growth
factor (EGF, Spiliotis et al. 2003, 2006), the insulin/
insulin-like growth factor (Ins/IGF)-receptor
families (Konrad et al. 2003) and the surface serine/
threonine kinases of the closely-related transforming
growth factor-beta (TGF-b) and bone morpho-
genetic protein (BMP)-receptor families (Zavalo-
Gongora et al. 2006). A cytokine of E. multilocularis
which has signiﬁcant homology to mammalian
EGF is substantially upregulated in metacestodes
cultured under conditions that promote growth
and diﬀerentiation (Spiliotis et al. 2003). Also,
EmSkip, a novel member of the SNW/SKIP family
of transcriptional co-regulators was shown to be ex-
pressed in the Echinococcus metacestodes (including
protoscoleces) during an infection of the intermedi-
ate host (Gelmedin et al. 2005). EmSkip interacts
with EmSmadA and EmSmadB, two TGF-b/BMP
signal transducers of E. multilocularis (see Zavalo-
Gongora et al. 2003), indicating a role for this
protein in TGF-b signalling processes in this
parasite. In addition, the downstream signalling
elements of the MAP kinase cascade have been
identiﬁed and characterized (Spiliotis and Brehm,
2004; Spiliotis et al. 2005, 2006). The Echinococcus
MAP kinase cascade factors share molecular simila-
rities to, but also diﬀer in particular aspects from,
their mammalian counterparts, and thus represent
prime candidate targets for the development of novel
anthelminthic drugs. This has been further sub-
stantiated via analysis of receptor activation, which
has shown that the E. multilocularis insulin receptor
EmIR interacts readily with insulin from the host,
and TGF-breceptor EmTR1 and possibly also the
EGF-receptor EmER can interact with their corre-
sponding host ligands (reviewed by Brehm et al.
2006). Thus, parasite and host have evolved means
of communication that would largely inﬂuence the
developmental biology of both parasite and host.
The evidence indicates that these receptor-ligand
systems play a central role in host-parasite interac-
tion processes and thus represent interesting drug
targets (Brehm et al. 2006). Cancer research has
generated an enormous number of compounds
which interfere with the functional activities of
homologuous receptors or respective downstream
kinases (see Sioud and Leirdal, 2007), and it will
be the challenge now to identify drugs, or deriva-
tives, which inhibit these receptors or the corre-
sponding downstream enzymes in a parasite-speciﬁc
manner.
(iv) In silico approaches
Mathis et al. (2005) employed current genomic
sequence information to deﬁne a drug target in
Echinococcus in silico, and subsequently conﬁrmed
their hypothesis experimentally. In bacteria, the
ribosomes are important antibiotic targets, and
macrolides such as erythromycin and clarithromycin
are agents which bind to the nascent peptide
exit tunnel near the peptidyltransferase centre of
large subunit ribosomal RNA (rRNA) (Rodriguez-
Fonseca et al. 1995). Higher eukaryotes carry a
guanine at position 2058 of both cytoplasmic and
mitochondrial rRNAs, and this modiﬁcation at this
position has been demonstrated to confer the resist-
ance of eukaryotic cells to macrolide antibiotics. In
contrast, the mitochondrial rRNA of E. multi-
locularis carries an adenine at sequence position
2058, which would be predictive for susceptibility
(Sander et al. 1997), while the nucleus-encoded
rRNA is characterized by a guanine at 2058 (Mathis
et al. 2005). Upon in vitro culture of E. multilocularis
metacestodes with clarithromycin, parasites, as
expected, exhibited severely impaired growth
characteristics, presented morphologically altered
mitochondria and displayed a lack of microtriches,
all in a dose-dependent manner. Adult worms were
also severely aﬀected, lost their motility and dis-
played morphological alterations, such as shortening
and constriction of proglottids and increased vacuo-
lization. Mathis et al. (2005) were the ﬁrst workers to
employ a sequence-based in silico approach for the
exploration of drugs whose mode of action was well
studied at the molecular level and whose corre-
sponding target was precisely deﬁned. However, a
prerequisite for such an approach is the availability
of comprehensive genome sequence information for
Echinococcus species.
CONCLUDING REMARKS
As outlined in this review, considerable eﬀorts have
been made to improve the therapeutical options for
the treatment of CE and AE. The benzimidazole-
based treatment regimens have improved consider-
ably the prognosis of patients but, due to the obvious
setbacks, new developments are needed. Compounds
that not only act as parastostatics but also as para-
sitocidals in vivo have not been discovered to date,
but it is conceivable that such compounds actually
exist. Thus, the current situation for aﬀected patients
is far from satisfactory. Academic institutions can
provide a scientiﬁc basis that could eventually
lead to novel treatment options, but ﬁnancial con-
straints constantly limit the further development of
promising avenues. Thus, considerably more input
and support is needed from the pharmaceutical and
biotechnological industries as well as governmental
agencies to provide solutions for these neglected
diseases. The novel genomic resources developing
the discovery of the receptor-ligand interactions and
associated signalling pathways which inﬂuence the
parasite-host interaction, and the further character-
ization of immuno-modulatory molecules provide
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new and exciting opportunities and promising
targets for future studies of novel chemotherapeutical
and immuno-therapeutical options for CE and AE.
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